INDICATIONS FOR TRANSFUSING NAT UNTESTED BLOOD PRODUCTS- ARE THESE RATIONAL?
(Abstract release date: 05/19/16)
EHA Library. Ali S. 06/09/16; 135126; PB2226
Dr. Sidra Ali
Contributions
Contributions
Abstract
Abstract: PB2226
Type: Publication Only
Background
Blood transfusion is a life-saving therapeutic option in many conditions. However, blood transfusion is never safe and is associated with risks of transfusion transmitted infections (TTI). To minimize the risk of TTI, all blood donations are screened for infectious diseases as per W.H.O standard. In emergency situation where blood products are required urgently and screened products are unavailable, it may be necessary to transfuse unscreened or partially screened blood products. Some of the indications where use of such products can be justified include: Critical Laboratory Results (defined as Hb < 7gm/dl and platelets < 20 x 109/L), active bleeding, emergency surgical/ radiological intervention and sepsis. Irrational transfusion of unscreened blood puts a patient at risk of acquiring an infectious disease which can cause severe long term complications. So it is very important they must only be transfused in dire need when screened products are not available and transfusion is the only life-saving option. In our hospital all products are serologically tested and then all sero-negative samples undergo molecular testing known as Nucleic acid testing (NAT). The rate and indications of dispensing NAT untested blood products in our hospital is unknown
Aims
The aim of this study is to recognize the indications for transfusing NAT untested blood products and assess whether these are rational or not.
Methods
This was a clinical audit conducted by Blood Bank, Section of Haematology, Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital. The Study duration was from May-July 2015. All the request forms received to Blood bank requesting release of NAT untested blood products were reviewed. Additional information regarding the need and indication was extracted from the online integrated laboratory data and medical record chart of patients. Data was recorded on a predesigned proforma. Statistical package for social sciences version 19 was used for data analysis.
Results
During the study period, 254 requisition slips were received to blood bank for 234 patients. Six hundred and seventy two NAT untested blood products were released during study period. The products released included: 154 packed red cell, 493 random donor platelets and 25 whole blood units. Most of the cases where blood bank was not able to provide screened blood were from Section of Clinical Haematology (n=61, 24%) followed by General Surgery (n=46, 18%) and Internal Medicine (n=40, 16%). The location of patients was Emergency room (n=58, 23%), Operating room (n=46, 18%), Wards (n=45, 18%) and special care units (n=28, 11%).In 224 out of 254 (88.2%) requests, the indications for transfusion were rational. The most common indication for the release of NAT untested products was Critical Laboratory results (n=106, 42%) followed by Surgical/Radiological Intervention (n=65, 26%) active bleeding (n=53, 21%) and sepsis (n=12, 5%). Seven percent (18/254) of the requests were not fulfilling any of the indication and transfusion in these cases was not justified. Majority of these requests (n=14, 77.8%) were from oncology day care transfusion area.
Conclusion
Majority of the indications for transfusion of NAT untested products were rational (93%). Few cases of irrational transfusion of NAT untested products were identified. The audit identified the areas in the hospital which need re-inforcement on the rational use of NAT untested blood products.
Session topic: E-poster
Keyword(s): Transfusion
Type: Publication Only
Background
Blood transfusion is a life-saving therapeutic option in many conditions. However, blood transfusion is never safe and is associated with risks of transfusion transmitted infections (TTI). To minimize the risk of TTI, all blood donations are screened for infectious diseases as per W.H.O standard. In emergency situation where blood products are required urgently and screened products are unavailable, it may be necessary to transfuse unscreened or partially screened blood products. Some of the indications where use of such products can be justified include: Critical Laboratory Results (defined as Hb < 7gm/dl and platelets < 20 x 109/L), active bleeding, emergency surgical/ radiological intervention and sepsis. Irrational transfusion of unscreened blood puts a patient at risk of acquiring an infectious disease which can cause severe long term complications. So it is very important they must only be transfused in dire need when screened products are not available and transfusion is the only life-saving option. In our hospital all products are serologically tested and then all sero-negative samples undergo molecular testing known as Nucleic acid testing (NAT). The rate and indications of dispensing NAT untested blood products in our hospital is unknown
Aims
The aim of this study is to recognize the indications for transfusing NAT untested blood products and assess whether these are rational or not.
Methods
This was a clinical audit conducted by Blood Bank, Section of Haematology, Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital. The Study duration was from May-July 2015. All the request forms received to Blood bank requesting release of NAT untested blood products were reviewed. Additional information regarding the need and indication was extracted from the online integrated laboratory data and medical record chart of patients. Data was recorded on a predesigned proforma. Statistical package for social sciences version 19 was used for data analysis.
Results
During the study period, 254 requisition slips were received to blood bank for 234 patients. Six hundred and seventy two NAT untested blood products were released during study period. The products released included: 154 packed red cell, 493 random donor platelets and 25 whole blood units. Most of the cases where blood bank was not able to provide screened blood were from Section of Clinical Haematology (n=61, 24%) followed by General Surgery (n=46, 18%) and Internal Medicine (n=40, 16%). The location of patients was Emergency room (n=58, 23%), Operating room (n=46, 18%), Wards (n=45, 18%) and special care units (n=28, 11%).In 224 out of 254 (88.2%) requests, the indications for transfusion were rational. The most common indication for the release of NAT untested products was Critical Laboratory results (n=106, 42%) followed by Surgical/Radiological Intervention (n=65, 26%) active bleeding (n=53, 21%) and sepsis (n=12, 5%). Seven percent (18/254) of the requests were not fulfilling any of the indication and transfusion in these cases was not justified. Majority of these requests (n=14, 77.8%) were from oncology day care transfusion area.
Conclusion
Majority of the indications for transfusion of NAT untested products were rational (93%). Few cases of irrational transfusion of NAT untested products were identified. The audit identified the areas in the hospital which need re-inforcement on the rational use of NAT untested blood products.
Session topic: E-poster
Keyword(s): Transfusion
Abstract: PB2226
Type: Publication Only
Background
Blood transfusion is a life-saving therapeutic option in many conditions. However, blood transfusion is never safe and is associated with risks of transfusion transmitted infections (TTI). To minimize the risk of TTI, all blood donations are screened for infectious diseases as per W.H.O standard. In emergency situation where blood products are required urgently and screened products are unavailable, it may be necessary to transfuse unscreened or partially screened blood products. Some of the indications where use of such products can be justified include: Critical Laboratory Results (defined as Hb < 7gm/dl and platelets < 20 x 109/L), active bleeding, emergency surgical/ radiological intervention and sepsis. Irrational transfusion of unscreened blood puts a patient at risk of acquiring an infectious disease which can cause severe long term complications. So it is very important they must only be transfused in dire need when screened products are not available and transfusion is the only life-saving option. In our hospital all products are serologically tested and then all sero-negative samples undergo molecular testing known as Nucleic acid testing (NAT). The rate and indications of dispensing NAT untested blood products in our hospital is unknown
Aims
The aim of this study is to recognize the indications for transfusing NAT untested blood products and assess whether these are rational or not.
Methods
This was a clinical audit conducted by Blood Bank, Section of Haematology, Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital. The Study duration was from May-July 2015. All the request forms received to Blood bank requesting release of NAT untested blood products were reviewed. Additional information regarding the need and indication was extracted from the online integrated laboratory data and medical record chart of patients. Data was recorded on a predesigned proforma. Statistical package for social sciences version 19 was used for data analysis.
Results
During the study period, 254 requisition slips were received to blood bank for 234 patients. Six hundred and seventy two NAT untested blood products were released during study period. The products released included: 154 packed red cell, 493 random donor platelets and 25 whole blood units. Most of the cases where blood bank was not able to provide screened blood were from Section of Clinical Haematology (n=61, 24%) followed by General Surgery (n=46, 18%) and Internal Medicine (n=40, 16%). The location of patients was Emergency room (n=58, 23%), Operating room (n=46, 18%), Wards (n=45, 18%) and special care units (n=28, 11%).In 224 out of 254 (88.2%) requests, the indications for transfusion were rational. The most common indication for the release of NAT untested products was Critical Laboratory results (n=106, 42%) followed by Surgical/Radiological Intervention (n=65, 26%) active bleeding (n=53, 21%) and sepsis (n=12, 5%). Seven percent (18/254) of the requests were not fulfilling any of the indication and transfusion in these cases was not justified. Majority of these requests (n=14, 77.8%) were from oncology day care transfusion area.
Conclusion
Majority of the indications for transfusion of NAT untested products were rational (93%). Few cases of irrational transfusion of NAT untested products were identified. The audit identified the areas in the hospital which need re-inforcement on the rational use of NAT untested blood products.
Session topic: E-poster
Keyword(s): Transfusion
Type: Publication Only
Background
Blood transfusion is a life-saving therapeutic option in many conditions. However, blood transfusion is never safe and is associated with risks of transfusion transmitted infections (TTI). To minimize the risk of TTI, all blood donations are screened for infectious diseases as per W.H.O standard. In emergency situation where blood products are required urgently and screened products are unavailable, it may be necessary to transfuse unscreened or partially screened blood products. Some of the indications where use of such products can be justified include: Critical Laboratory Results (defined as Hb < 7gm/dl and platelets < 20 x 109/L), active bleeding, emergency surgical/ radiological intervention and sepsis. Irrational transfusion of unscreened blood puts a patient at risk of acquiring an infectious disease which can cause severe long term complications. So it is very important they must only be transfused in dire need when screened products are not available and transfusion is the only life-saving option. In our hospital all products are serologically tested and then all sero-negative samples undergo molecular testing known as Nucleic acid testing (NAT). The rate and indications of dispensing NAT untested blood products in our hospital is unknown
Aims
The aim of this study is to recognize the indications for transfusing NAT untested blood products and assess whether these are rational or not.
Methods
This was a clinical audit conducted by Blood Bank, Section of Haematology, Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital. The Study duration was from May-July 2015. All the request forms received to Blood bank requesting release of NAT untested blood products were reviewed. Additional information regarding the need and indication was extracted from the online integrated laboratory data and medical record chart of patients. Data was recorded on a predesigned proforma. Statistical package for social sciences version 19 was used for data analysis.
Results
During the study period, 254 requisition slips were received to blood bank for 234 patients. Six hundred and seventy two NAT untested blood products were released during study period. The products released included: 154 packed red cell, 493 random donor platelets and 25 whole blood units. Most of the cases where blood bank was not able to provide screened blood were from Section of Clinical Haematology (n=61, 24%) followed by General Surgery (n=46, 18%) and Internal Medicine (n=40, 16%). The location of patients was Emergency room (n=58, 23%), Operating room (n=46, 18%), Wards (n=45, 18%) and special care units (n=28, 11%).In 224 out of 254 (88.2%) requests, the indications for transfusion were rational. The most common indication for the release of NAT untested products was Critical Laboratory results (n=106, 42%) followed by Surgical/Radiological Intervention (n=65, 26%) active bleeding (n=53, 21%) and sepsis (n=12, 5%). Seven percent (18/254) of the requests were not fulfilling any of the indication and transfusion in these cases was not justified. Majority of these requests (n=14, 77.8%) were from oncology day care transfusion area.
Conclusion
Majority of the indications for transfusion of NAT untested products were rational (93%). Few cases of irrational transfusion of NAT untested products were identified. The audit identified the areas in the hospital which need re-inforcement on the rational use of NAT untested blood products.
Session topic: E-poster
Keyword(s): Transfusion
{{ help_message }}
{{filter}}